Biotechnology Today

https://www.harrisonacademicpress.com/index.php/BT

Vol 1, Issue 1, 2026

A Prospective Study on Computer-Aided Drug Design and Drug Discovery

1. **G. Udaya***, Asst. Professor, DEPT OF Pharmacology,
2. N. Praveen Kumar, Asso. Professor, DEPT OF PHARMACEUTICS,
3. A. RANI, Asso. Professor, DEPT OF PHARMACEUTICS,
4. **A. RAVI KUMAR**, Asso. Professor, DEPT OF PHARMACOLOGY,
5.**Dr.M. SREENIVASULU**, PRINCIPAL, NARAYANA PHARMACY COLLEGE,
[1,2,3,4,5] NARAYANA PHARMACY COLLEGE, CHINTHA REDDY PALEM, NELLORE

Abstract: Computer-Aided Drug Design (CADD), which bridges the fields of biology and technology, is a revolutionary force in the ever-changing field of drug development.The historical development of CADD, its classification into structure-based and ligand-based approaches, and its critical function in streamlining and accelerating drug discovery are all covered in this study. As CADD develops, protecting data privacy and integrating a variety of biological data become critical.There are still issues that need strong ethical frameworks and algorithm optimisation.CADD's predictive power is increased by combining machine learning and artificial intelligence, yet scalability issues and ethical issues still exist. Platforms like Open-Source Malaria serve as examples of worldwide initiatives and collaborative efforts that highlight the democratisation of medication research. Although there are ethical conundrums and accessibility issues to be resolved, the intersection of CADD and personalised medicine provides customised therapeutic treatments. Green chemistry, immersive technology, and quantum computing are examples of emerging technologies that have the potential to completely change CADD in the future. Rapid developments in CADD's trajectory foreshadow difficulties in guaranteeing accuracy, mitigating AI biases, and integrating sustainability indicators.In order to create a healthier, more promising future for drug development, this paper's conclusion emphasises the need of taking proactive steps in traversing the ethical, technical, and pedagogical boundaries of CADD.

Keywords: Computer-Aided Drug Design (CADD); Machine Learning and Artificial Intelligence (AI);drug discovery; Chemoinformatics; molecular modeling; molecular docking; target identification

1. IntroductiontoComputer-AidedDrugDesign(CADD)

Computer-AidedDrugDesign(CADD):ASynthesisofBiologyandTechnology

In the vast field of drug discovery, where biology and chemistry meet, finding and creating a new therapeutic agent may be a time-consuming and costly process. In the past, this process has depended on chance findings or conventional trial-and-error techniques, sometimes taking decades and significant resources with little assurance of success. With the advent of Computer-Aided Drug Design (CADD) in the late 20th century, this field entered a transformative era that combines the predictive power of computational algorithms with the intricate complexities of biological systems and the creation of databases curated from both chemical and biological data [1].The use of computer algorithms on chemical and biological data to model and forecast how a therapeutic molecule will interact with its target—typically a protein or DNA sequence in the biological system—is the fundamental idea behind CADD [2].This may include anticipating the pharmacological effects and possible adverse effects, as well as comprehending the drug's molecular structure or target and predicting how the medication will bind.

Two significant developments contributed to the development of CADD: the burgeoning field of structural biology, which revealed the three-dimensional structures of biomolecules, and the exponential increase in computing power, which allowed for the execution of complex simulations in comparatively shorter amounts of time [3].Among the oldest and most One of CADD's most well-known uses was in the creation of the anti-influenza medication Zanamivir. This procedure demonstrated how this strategy may drastically save the time needed for drug discovery [4]. Fundamentally, CADD is separated into two primary groups: ligand-based drug design (LBDD) and structure-based drug design (SBDD) [5].In order to comprehend how possible medications could fit and interact with the biological target, SBDD makes use of information about its three-dimensional structure.To create novel drug candidates, LBDD, on the other hand, focusses on existing drug compounds and their pharmacological properties rather than the target structure (Figure 1) [6].




Figure 1. Conventional pathways in structure-based drug design (SBDD) and ligand-based drugdesign (LBDD) employ distinct methodologies. SBDD centers on target biomolecule structures, whileLBDD relies on known ligand characteristics [7].

The emergence of CADD is closely linked to the paradigm change in drug discovery, which saw the process become more focused and logical rather than primarily empirical [8]. But like any scientific approach, CADD has drawbacks. It's critical to recognise the inherent risks when making predictions about biological system behaviour based only on computer simulations.Take the fictitious situation, for example, when a computer simulation faithfully captures the molecular interactions between a receptor and its target.However, the predictions could differ greatly from the actual results if the simulation is missing important real-world data on external environmental conditions or unanticipated biological reactions.Despite their sophistication, these models often need experimental validation to confirm their predictions [9, 10]. In summary, CADD stands for the harmonic fusion of biology and technology with the goal of accelerating drug discovery.Even while it has already advanced the area significantly, better computational techniques and a deeper understanding of biological processes will be necessary to fully realise its promise.

2. KeyTechniquesandApproachesinCADD

DelineatingtheArrayofTechniquesinComputer-AidedDrugDesign

Computer-Aided Drug Design (CADD) is a powerful and interdisciplinary field that playsapivotalroleinmoderndrugdiscovery.Itcombinescomputationaltechniqueswith biologicalknowledgetoidentifyandoptimizepotentialdrugcandidates.Thisintegration of diverse methodologies

its diverse methodologies, ranging from molecular modeling to predicting drug metabolism. Within CADD, adherence to Lipinski's rule is paramount for achieving optimal oral drug likeliness, where compounds ideally minimize violations of criteria such as molecularweight,lipophilicity,hydrogenbonddonors,andacceptors.Thisstrategicintegration of CADD principles and adherence to drug-likeness criteria collectively accelerates and refinesthedrugdiscoveryprocess,showcasingtheversatilityandimpactfulroleofCADD in various fields and the pharmaceutical industry (Figure 2) [11,12].




Figure2. Elements of processing biomolecular data for CADD (image sourced from the European Research Council website [13]).

Molecular Modelling: The core of CADD is molecular modelling, which encompasses a variety of computer methods for simulating or modelling molecular behaviour.This entails building three-dimensional representations of molecular structures, often including ligands and proteins.A greater comprehension of how possible medications could interact within the biological system is made possible by this method, which offers insights into the structural and functional properties of molecules [14].It helps in the creation and optimisation of possible medications by allowing researchers to see and examine the interactions between drug candidates and their target proteins. Protein structure prediction has been greatly sped by recently developed AI/ML-driven tools such as AlphaFold2 [15], trTosetta [16,17], Robetta [18], RoseTTA Fold [19], ESMFold [20], and OmegaFold [21] [22]. Through different tools like Gromacs [23], ACEMD [24], and OpenMM [25,26], techniques such as molecular dynamics (MD) simulations may predict the time-dependent behaviour of molecules, capturing their movements and interactions throughout time (Table 1).

Docking and Virtual Screening: Docking is the process of predicting a drug molecule's orientation and position upon binding to its target protein.An important factor in drug design is the estimation of the binding affinity between the medication and its target [27]. Researchers may accurately estimate binding affinities and orientations by using sophisticated programs like AutoDock Vina [28], AutoDock GOLD [29], Glide [30], DOCK [31], Ligand-Fit [32], and SwissDock [33] (Table 2).On the other hand, a complementary method called virtual screening entails searching through large chemical libraries to find possible drug candidates [34]. This procedure is aided by tools such as DOCK [26], LigandFit [27], and ChemBioServer [35], which quickly assess interactions and find molecules with high binding affinities. LigandFit integrates into the Schrödinger suite, DOCK is well-known for structure-based drug design, and ChemBioServer provides an online platform for effective virtual screening.In the complicated world of computational drug design, the combination of these docking and virtual screening methods improves prediction accuracy and greatly aids in the discovery of interesting drug candidates. Numerous scholars, such as Pinzi and Sohoo, have substantiallyspoke about the use of these tools, demonstrating how they are being used to advance computational drug design [36,37].

Table1. Structure-predictingmethodsandtools.

Methods	Programs
Homology Modeling/Comparative Modeling: Create a 3D model of the target protein using a homologous protein's empirically confirmed structure as a guide.	
AbInitioModeling: Builda3Dmodelofthetargetproteinby sampling the protein's conformational space without using experimental data.	
Threading: Build a 3D model of the target protein by aligningtheprotein sequence with the sequences of	

f knownstructure.	
Hybrid Modeling:Combine two or more modeling approachesto improve the accuracy of the predicted structure.	MODELLER,SWISS-MODEL, Phyre2,RaptorX,I-TASSER
Molecular Dynamics: Simulate the behavior of the protein overtime using classical or quantum mechanics.	Rosetta,QUARK,AlphaFold , ESMFold, PCONS5
Knowledge-based methods: Use existing knowledge aboutprotein structure and function to predict the structure of thetarget protein.	MUSTER,3D-PSSM, LOMETS,HHpred
Template-free methods: Build a 3D model of the target proteinwithout using templates or homologous proteins.	CABS-flex,PrimeX, GalaxyHomomer
Fragment-assembly methods: Build a 3D model of the target proteinbyassemblingfragmentsofknownproteinstructures.	GROMACS,NAMD, CHARMM ProSMoS,ProQ3D, I-TASSER-2GO CONFOLD2,MetaPSICOV, TrRosetta PEP-FOLD3, Robetta,QUARK

Table2. DockingTools,theiradvantages,anddisadvantages.

Tool	Application	Advantages	Disadvantages
AutoDock Vina	Predicting the binding affinities and orientations ofligands.	Fast, accurate, andeasy to use.	May not be asaccurate for complexsystems.
AutoDockGOLD	Predictingthebinding affinities and orientations of ligands, especially for flexible ligands.	Accurateforflexible ligands.	Requiresalicenseandcan be expensive.
Glide	Predicting the binding affinities and orientations of ligands.	Accurate and integratedwithother Schrödinger tools.	Requires theSchrödinger suite,which can beexpensive.
DOCK	Predicting the binding affinitiesandorientations ofligandsandperforming virtual screening.	It is versatile and canbe used for bothdocking and virtualscreening.	Can be slower thanother tools.
LigandFit	Predicting the binding affinities and orientations of ligands.	Easy to use andintegrated with otherSchrödinger tools.	May not be asaccurate for complexsystems.
SwissDock	Predicting the binding affinities and orientations ofligands.	Easy to use andaccessibleonline.	May not be asaccurate for complexsystems.

The link between a molecule's chemical structure and biological activity is investigated via quantitative structure-activity relationship (QSAR) modelling. By using statistical techniques, QSAR models are able to forecast the pharmacological activity of novel compounds based on their structural characteristics. This allows chemists to make well-informed changes to improve a drug's potency or lessen its negative effects [38, 39]. The Similarity Ensemble Approach (SEA) was a key instrument used in a study by Luo et al. to assess the accuracy of k-nearest neighbours (kNN) Quantitative Structure-Activity Relationship (QSAR) models. In order to identify active and inactive compounds, these models were methodically built for known ligands connected to specific G Protein-Coupled Receptor (GPCR) targets [40]. In a different study, Raj et al. employed the molecular field analysis approach to create QSAR models for 50 drugs that showed anti-HIV activity.The results emphasised how important electrostatic and steric interactions are in determining the compounds' anti-HIV efficacy [41].Additionally, a unique method was used in another research by Nigsch et al. that combined QSAR models with a deep neural network to examine a wide range of 1000 compounds with anti-cancer properties. This work found that combining the QSAR method with deep learning techniques was beneficial, allowing for the discovery of crucial structural features that greatly enhanced the anti-cancer effectiveness of the drugs [42].
The spatial arrangement of key characteristics of a molecule that are required for its pharmacological action is known as a pharmacophore. A key element of modern drug development is pharmacophore modelling, which entails determining the spatial arrangements of basic molecular characteristics that are necessary to a molecule's pharmacological action.For medicinal chemists, this method is powerful because it allows for the logical creation of new molecules with ideal pharmacological characteristics [43]. Pharmacophore modelling, for instance, has been useful in the development of kinase inhibitors. Zhang et al. identified key characteristics of active kinase inhibitors, such as hydrophobic areas, acceptors, and hydrogen bond donors, using pharmacophore modelling.Improved selectivity and efficacy against particular kinases implied in disease pathways were the results of the discovered pharmacophore elements, which offered useful assistance for creating new compounds [44]. Similarly, ligands that target G protein-coupled receptors (GPCRs) have been designed using pharmacophore modelling.By clarifying the spatial arrangement of characteristics essential for GPCR binding, such hydrogen bonds and aromatic interactions, Fidom et al. provided an example of this use [45,46]. The creation of ligands with improved affinity and selectivity for certain GPCRs engaged in various therapeutic domains was made easier by the pharmacophore models that were produced.In conclusion, the methodical examination of the key elements influencing a molecule's pharmacological action is made possible by the strategic use of pharmacophore modelling.This information helps researchers better understand ligand-receptor interactions and allows them to create molecules in the future. with improved effectiveness and fewer adverse effects, influencing the direction of pharmaceutical development in the future.
Drug Metabolism and Pharmacokinetics Prediction (DMPK): The capacity of a medicine to connect to its target is not the only factor that determines its eventual success. Important factors include its solubility, metabolic stability, and pharmacokinetics—the way it is transported throughout the body. By providing methods for predicting a compound's DMPK characteristics, CADD enables researchers to foresee and resolve any problems with drug metabolism, bioavailability, and possible drug-drug interactions [47].
NovoDrugDesign:Denovo drug design generates new drug molecules from the ground up, in contrast to other approaches that alter preexisting compounds. This method opens the door to several new therapeutic candidates by using computational algorithms to create new chemical structures that meet certain criteria [48].
In conclusion, the methods included within CADD provide a comprehensive, multifaceted strategy for drug discovery.By providing a set of instruments that cover molecular CADD guarantees that drug candidates are powerful, selective, and have the best pharmacokinetic and safety profiles by modelling drug metabolism.

3. IntegrationofMachineLearningandAIinCADD

MachineLearningandAI:TheNewVanguardinDrugDiscovery

The technological renaissance that defines the 21st century has borne witness to the meteoric rise of Machine Learning (ML) and Artificial Intelligence (AI). These computa- tional realms, known for their data-driven decision-making capabilities, have begun to significantly influence the sphere of Computer-Aided Drug Design (CADD), reshaping the contoursofdrugdiscovery[49].MachineLearning,asubsetofAI,hingesonalgorithms that can learn patterns from vast data sets without being explicitly programmed for specific tasks (Figure 3) [50]. In drug discovery, ML has been instrumental in predicting molecular properties, understanding drug-receptor interactions, and forecasting biological responses based on chemical structures. Techniques such as deep learning, which uses neural net- works modeled after the human brain, show immense potential for predicting complexdrug-related outcomes with remarkable accuracy [51].




Figure3. SubsetsofArtificialIntelligence: MachineLearningandDeepLearning.

ImplicationsofMLinCADD

Drug-Drug Interaction Prediction: One of the difficulties in drug development is figuring out how a new treatment can affect other prescriptions a patient may be taking. Large datasets of existing drug-drug interactions may be processed by ML systems to forecast potentially hazardous combinations for new substances [52].
Drug Repurposing: This process entails giving already-approved medications new therapeutic uses. Machine Learning may save time and money compared to conventional drug development by identifying possible novel targets for current drugs via the analysis of large datasets [53].
Generative Adversarial Networks (GANs) in Drug Design: GANs are a kind of artificial intelligence in which two neural networks—a discriminator and a generator—are trained simultaneously. While the discriminator evaluates them, the generator produces molecular structures.The generator gradually improves its ability to produce viable and perhaps bioactive molecular structures that may be produced and examined in a laboratory setting [54].

Predictive toxicology: Unexpected toxicity is one of the main causes of drug candidates' failure in clinical trials. By examining past data on drug-induced toxicity, machine learning models may assist in predicting possible negative effects and weeding out potentially harmful compounds early in the discovery process. Furthermore, QSAR models predict toxicological effects by correlating a molecule's structure with its probable toxicity using descriptors such as molecular weight, lipophilicity, and electrical characteristics.Other descriptors, like In computational toxicology, assolubility, metabolic stability, and toxicophore identification provide comprehensive insights that aid in early hazard detection and compound prioritisation for experimental testing.
More than only the acceptance of new technology is shown by the incorporation of AI and ML into CADD.Using massive data and computing capacity to influence decisions at every stage of drug development, it marks a paradigm change from conventional hypothesis-driven research to data-driven discovery [55].Nevertheless, difficulties still exist even if these technologies hold up the prospect of revolutionising drug discovery. This integration continues to focus on issues like data quality, the interpretability of AI models, and the need for experimental validation [56].Essentially, a new era in drug discovery is ushered in by the combination of ML, AI, and CADD. an age marked by faster delivery of effective therapies to patients, lower prices, and better efficiency.

4. ChallengesandLimitationsinCADD

UnderstandingtheObstacles:TheRoadblocksinComputer-AidedDrugDesign

Although CADD has unmatched benefits for accelerating and improving drug development, it is important to understand its inherent drawbacks. The lack of AI/ML specialists in CADD is a significant barrier.Initiatives like targeted recruiting and specialised training programs are essential. For instance, companies like in-silico Medicine are leading the charge to close this gap by developing a workforce with the expertise to use cutting-edge computational tools for drug development. Resolving these constraints may result in improved tactics and open the door to more efficient drug discovery processes [57]. Predictive model accuracy:Since docking scores, machine learning predictions, and molecular dynamics simulations all depend on theoretical models, one of the main challenges in CADD is guaranteeing the correctness of computational models. The many subtleties of biological systems may not be well represented by these models.Exploring the complexities of scoring systems is crucial to improving accuracy [58]. In drug development, scoring systems are essential for forecasting how well compounds will attach to their targets. It is essential to actively reduce the danger of false positives and negatives in order to assure accuracy. This entails careful scoring parameter calibration, the use of several chemical descriptors, and ongoing validation against experimental data. For example, the dependability of predictions may be improved by fine-tuning docking scores via thorough validation against known binding affinities.Researchers can increase confidence by balancing sensitivity and specificity in the best possible way.algorithms, decreasing the possibility that drug discovery predictions may be inaccurate [59–61].
Data Quantity and Quality: The quality of the data used to train CADD tools determines how accurate their predictions are.If the

underlying data is inadequate or of low quality, the forecasts are probably wrong.One persistent issue is the dearth of well selected, superior datasets, particularly when it comes to machine learning in drug development [62]. Molecular interaction datasets may be improved by eliminating outliers and making sure that data formatting is consistent. This will reduce errors and increase the dependability of computational models. Standardised experimental procedures, such consistent endpoint measurements and assay settings, are also used to enhance data quality in CADD and guarantee reliable and strong findings.

Excessive dependence on Computational forecasts: Although CADD is an effective tool, relying too much on its forecasts without further experimental verification may result in misdirected efforts.A effective drug development process requires striking a balance between experimental data and computer predictions [63].
Time and computer Cost: Some sophisticated CADD methods need a significant amount of computer power, particularly when they use complex machine learning models or lengthy molecular dynamics simulations.Some research organisations may find the accompanying time and infrastructure expenses prohibitive [64].
Representing Molecular Flexibility: The majority of biological molecules, including target proteins and possible pharmacological substances, are very flexible.Representing This adaptability is difficult and may have a big influence on the outcomes of CADD research, particularly when it comes to methods like molecular docking [65].
AI Model Interpretability:It becomes harder to understand the predictions made by AI and machine learning models as they get more sophisticated. It may be difficult to comprehend why a certain molecule is anticipated to be active or how its structure could be optimised due to the "black-box" nature of AI models [66].
The potential advantages of CADD in drug discovery are significant, notwithstanding these difficulties.CADD will continue to lead the way in contemporary drug development and influence the direction of therapeutics by recognising these constraints and working tirelessly to overcome them via innovation and research.

5. ExperimentalValidationinCADD:FromIn-SilicototheLabBench

BridgingComputationalPredictionswithReality

Computer-Aided Drug Design (CADD) outputs at the nexus of drug discovery need thorough experimental validation to validate their biological and therapeutic relevance. This collaboration between the computational and experimental domains is the only way to determine a drug's actual potential [67].
Computational forecasts, no matter how sophisticated, are always based on theoretical models. Biological systems may be roughly represented by these models, but there will always be differences.In order to ascertain if a projected molecule has true therapeutic potential or is just a computational artefact, experimental validation acts as the crucible [68]. Following the identification of possible medication candidates by the CADD method, the initial validation step is biochemical analysis.These assays provide information on binding affinities and potential modes of action by measuring the interaction between the proposed drug molecule and its intended target protein [69].Cell-based tests are used to learn more about the biological significance of a medication. By evaluating a compound's impact on cellular processes, these tests enable researchers to determine its possible toxicity and effectiveness in a more intricate, biologically relevant context [70]. Any medication candidate must have its pharmacokinetic, safety, and effectiveness assessed in vivo before moving on to human trials. This is accomplished by using animal models, which provide a more thorough insight of how a medicine would function in a real creature [71].
Atomic-level information of a drug's interaction with its target may be obtained using methods like NMR spectroscopy and X-ray crystallography.These kinds of discoveries may provide molecular understandings of drug action, improve drug design tactics, and confirm computational predictions [72]. Experimental validation often yields surprising results or unforeseen difficulties. Drug development is not a linear process; rather, it often entails iterations between experimental testing and CADD predictions, producing improved drug candidates and more sophisticated models [73].

Additionally, the first need is to choose software that is known for its accuracy in scoring simulation and prediction outcomes in order to guarantee solid and verified findings in CADD.A foundation of accuracy and dependability is established in the computational models by using well-validated tools, such AutoDock Vina or Schrödinger Suite. This paves the way for more reliable and significant insights in CADD simulations and forecasts.
Essentially, even if CADD offers a strong toolkit to direct and speed up drug development, the experimental world is where a medicine's value is ultimately determined. The foundation of contemporary drug development is this collaboration between computing and experimentation, which guarantees that only the most promising molecules make it from the digital realm to the patient's bedside.

6. HarnessingthePowerofAI:AParadigmShiftinDrugDiscovery

One of the biggest changes in contemporary drug discovery techniques is the introduction of artificial intelligence (AI) and machine learning (ML) into the field of computer-aided drug design (CADD).These mathematical techniques promise unprecedented enhanced precision, speed, and understanding of the intricate dance of molecular interactions [74]. The use of machine learning, a kind of artificial intelligence, in drug discovery has increased dramatically. ML systems learn from data, increasing their prediction capacity with each iteration, in contrast to conventional CADD approaches that use preset algorithms to anticipate molecular behaviour [75].

The capacity of ML to extract information and patterns from large datasets is one of its advantages in CADD.As biological data grows exponentially, machine learning models—particularly deep learning architectures—are able to uncover intricate correlations and characteristics that may not be immediately apparent to researchers [76].Using chemical structures, pharmacological characteristics, and even genetic information, machine learning models have proven crucial in forecasting drug

reactions. They also provide information about possible drug-drug interactions, which is important for maintaining drug safety [77].Advanced machine learning models, such variational autoencoders (VAEs) and generative adversarial networks (GANs), have recently been used to produce new chemical structures that may be therapeutic candidates, fusing the domains of computing and creativity [78].

High-dimensional data can be handled by machine learning models, particularly deep learning, which can also get around some of the drawbacks of conventional CADD, such the need for intensive feature engineering [79].Despite their enormous promise, AI and ML can cause worries. Interpretability, which is essential for scientific rigour, is hampered by the "black box" aspect of many deep learning models. Using patient data for model training raises a number of ethical issues [80]. In conclusion, the field of drug discovery is about to undergo revolutionary changes as CADD embraces the AI revolution. Future therapeutic advancements will be determined by how well and responsibly these technologies are integrated.

7. IntegrationofMulti-OmicsDatainCADD

HolisticViewpoints:EmbracingtheComplexityofBiologythroughMulti-OmicIntegration

With several levels of control and interaction, the biological systems that underlie disease states and medication interactions are complex.The genome, transcriptome, proteome, metabolome, and others are among the "omes" that must be examined in order to have a thorough knowledge.

A more comprehensive approach to drug development is ensured by including this multi-omics data into CADD [81].Although useful, single-omics research only provides a small portion of the biological jigsaw.Researchers may get a more thorough understanding of disease states, possible therapeutic targets, and general cellular dynamics by integrating many layers of omics data [82].Genomic data provides information about the similar genetic causes of diseases.When included into CADD, this data may help direct the search for pharmacological targets, particularly in diseases like certain types of cancer that have a significant genetic component [83]. All of the RNA molecules in a cell are represented by the transcriptome, which shows the genes that are actively being transcribed. At the mRNA level, integrating transcriptome data might provide information on how cells may react to a medication, perhaps indicating adverse effects or alternative routes [84]. Although genes and transcripts are important, medicines often target proteins directly. Understanding post-translational changes, possible off-target effects, and drug-protein interactions may all be aided by proteomic data [85].

Important information on a drug's metabolism, interactions with endogenous metabolites, and possible biomarkers for therapeutic effectiveness and toxicity may be found in metabolomics, the study of small molecules in biological systems [86]. A more integrated approach is used by systems biology, which goes beyond analysing distinct omics levels. Researchers may get a more comprehensive knowledge of drug action by predicting how medications may impact whole pathways or networks by building networks of interactions based on multi-omics data [87]. Although each "omics" layer offers priceless insights, when combined, they have the potential to completely transform CADD. Drug development may get closer to more individualised and efficient treatment options by embracing the complexity of biology via multi-omics integration.

8. CurrentChallengesinCADD

OvercomingBarriers:TheEvolvingLandscapeofChallengesinComputer-AidedDrugDesign

Drug discovery has been transformed by advances in Computer-Aided Drug Design (CADD), yet the area is not without its difficulties. These obstacles emphasise areas ripe for additional innovation, from data quality to the need for stronger predictive models [63]. The availability and quality of data are among the most basic issues.Computational predictions may be misled by dataset inaccuracies, such as inaccurate chemical structures or deceptive bioactivity data. Additionally, hoarding private data prevents expertise from being shared and consolidated [88]. Despite advancements, more predictive models are still required. Models may sometimes miss good candidates or generate false positives, especially when predicting drug-target interactions [89]. Biological macromolecules such as proteins and nucleic acids are dynamic. It is still very computationally challenging to account for this flexibility in simulations, particularly over extended durations [90]. Making sure that CADD approaches scale efficiently is essential as drug databases expand and models get more complex.This necessitates using cutting-edge computing infrastructure and continuously optimising algorithms [91]. The proliferation of biological data and multi-omics makes it difficult to meaningfully integrate these disparate information to improve drug development [92].

Since CADD often uses patient data, particularly in personalised medicine, protecting data privacy and resolving ethical issues related to data use are crucial [93]. In conclusion, resolving CADD's issues is crucial even as it continues to advance drug development. By addressing these challenges head-on, the sector can change, adapt, and keep moving in the direction of more successful and efficient drug development paradigms.

9. CaseStudies:SuccessStoriesinCADD

FromConcepttoClinic: TriumphsinComputer-AidedDrugDesign

Real success stories are generally the greatest way to understand the true influence of any scientific field. Numerous molecules have made the leap from the computer screen to clinical applications in Computer-Aided Drug Design (CADD), highlighting the promise of computational techniques [94].

HIV Protease Inhibitors: The discovery of protease inhibitors marked a major advancement in the fight against HIV/AIDS.Particularly in the creation of medications like saquinavir, CADD was essential.Potential binding pockets were discovered by researchers using molecular modelling and simulation, opening the door for more focused medication development [95].

Anti-influenza medications: Structure-based drug design was used to create the neuraminidase inhibitors, particularly oseltamivir (Tamiflu). Computational models helped identify therapeutic targets by examining the protein structures of influenza strains, which ultimately resulted in successful flu therapies [96]. Imatinib and Chronic Myeloid Leukaemia: CADD supported the development of imatinib (Gleevec), a ground-breaking medication for the treatment of chronic myeloid leukaemia. Imatinib is an example of how computational insights might result in powerful and selective inhibitors by targeting the BCR-ABLkinase [97]. HCV Inhibitors of Protease: In the past, treating hepatitis C was difficult.The advent of medications like boceprevir, which were created with substantial assistance from CADD, transformed HCV treatment.Researchers have discovered inhibitors that target the HCV protease using molecular dynamics and docking investigations [98]. Alzheimer's disease and inhibitors of β-secretase:Although the fight against Alzheimer's disease is still going on, CADD has helped to advance possible therapies. Inhibitors that target the β-secretase enzyme have been computationally developed; some of them, such donanemab and solanezumab, have advanced to clinical trials [99–101]. SARS-CoV: Researchers use sophisticated CADD techniques to identify leads for possible antiviral medications in the wake of the COVID-19 outbreak.Studies on the flavonoid glycosides found in medicinal plants have shown that they may have protective effects against COVID-19 infections. Possible inhibition of SARS-CoV-2 was proposed by docking experiments with alkaloids and derivatives of vanillin. Additionally, modelling studies that included both structure-based and ligand-based activities yielded insightful information, emphasising the multifaceted nature of computational chemistry in the search for efficient COVID-19 therapies [102].

When taken into consideration, these success stories perfectly capture the promise of CADD in contemporary drug development.They stand for advancement, optimism, and evidence of the cooperation between medicinal chemistry and computational techniques.

10. TheFutureofCADD:EmergingTechnologiesandInnovations

ChartingtheHorizon:NavigatingtheNextFrontiersofComputer-AidedDrugDesign

There is no denying CADD's revolutionary impact on drug discovery.Like any field that is always changing, there will be new opportunities and problems in the future. An age where drug development is quicker, more accurate, and more patient-centered may be unlocked by using cutting-edge technology and paradigms [103].When it comes to solving complicated drug design difficulties, traditional computers is limited. With its fundamentally distinct methods of controlling and processing information, quantum computing has the potential to completely transform molecular modelling and simulations, allowing for the exploration of enormous molecular areas in a matter of milliseconds [104].Researchers may get an intuitive grasp of molecular structures and interactions using immersive technology.Drug design may become a more tactile and visual endeavour using AR/VR, which will improve molecular modelling and collaborative efforts [105].CADD is quickly integrating machine learning, particularly deep learning. Neural networks can predict drug interaction toxicity and recommend new therapeutic compounds because of their capacity to identify patterns in large datasets [106].

CADD technologies that address unique genetic profiles will grow more popular as genomic sequencing becomes increasingly widespread. This will usher in a new age of really customised medications based on a person's genetic composition [107].Drug development may be made more accessible via collaborative and open-source platforms. These platforms may combine various knowledge and speed up the drug development process by using the collective intelligence of the worldwide scientific community [108].

Green chemistry concepts may be used into CADD to provide environmentally friendly and effective drug synthesis methods as environmental concerns gain traction [109].The future of CADD is promising in the broad context of drug development. Adopting new ideas and pushing technological limits will improve the field and ensure that everyone has access to better healthcare in the future.Utilising Global Intelligence in Computer-Aided Drug Design: Unity in Diversity

It is impossible to overestimate the importance of open-source platforms and collaborative networks in CADD in an increasingly linked society.These organisations provide a quick, democratic, and economical drug development process by amplifying the combined intellectual capacity of researchers throughout the globe [110].Conventional drug development is an exclusive endeavour that often requires enormous resources. This is made more accessible by open-source platforms, which enable researchers of diverse affiliations to use and contribute to cutting-edge CADD tools [111].This worldwide dedication is shown by programs such as the Open-Source Drug Discovery (OSDD) effort for TB [112].

CADD's crowdsourcing platforms leverage the power of global intelligence. These platforms offer challenges that lead to a variety of solution approaches, many of which may be unconventional but very successful [113].Open-source platforms guarantee the ongoing development of CADD tools.Community-driven tools are regularly updated in response to user input and the most recent developments in science [114–116].In a time of open access and collaboration, CADD's open-source platforms and collaborative networks stand out as rays of hope.They emphasise the idea that strength comes from togetherness and that the possibility of a healthy future is found in shared knowledge.Creating Boundaries in the Digital Age: Handling the Ethical and Regulatory Mazes of Computer-Aided Drug Development

The underlying ethical and regulatory issues provide vital milestones in the thrilling voyage of drug discovery using CADD.It becomes crucial to make sure that new digital technologies expedite drug discovery while upholding the highest ethical standards [117].

Data privacy is crucial given the growing use of patient data in personalised medicine. Strict data privacy rules are enforced by regulations such as the General Data privacy Regulation (GDPR), which govern the gathering, storage, and processing of personal data in research [118]. As CADD shifts towards more open-source and collaborative models, defining intellectual property rights may become unclear.Maintaining a balance between private and open-access claims guarantees that researchers and institutions get the recognition they deserve. [119]. Biases in training data may sometimes be inherited by AI-driven CADD techniques. For ethical drug development, it becomes crucial to make sure that these models are open, understandable, and

objective [120].In CADD, reproducibility—a pillar of scientific rigor—must be verified.Consistency in outcomes across various computational settings is crucial [121] as algorithms and models get more complicated. Although CADD is capable of forecasting possible therapeutic candidates, the shift to in vivo testing, particularly on animals, raises additional ethical issues. Guidelines for reducing animal experimentation and guaranteeing humane circumstances are provided by regulatory organisations [122].It is not enough for a medicine to be found using CADD to make it to market; regulatory agencies must approve and verify these methods.This approval procedure may be expedited by regulatory bodies and CADD experts working together [123].In conclusion, even if CADD has the potential to revolutionise drug development, it is crucial to conduct the process ethically and in accordance with current laws.As they say, "great power comes with great responsibility," and this is particularly true in the context of CADD.Looking Ahead: Imagining the Next Era of Computer-Aided Drug Development

There is still hope and innovation in the constantly changing field of CADD. However, it is full with obstacles and unknowns, just like any other cutting-edge subject. It is crucial to identify prospective paths and obstacles that might influence the next wave of medication development [124]. With a quantum revolution imminent, quantum computers have enormous potential to enhance drug design techniques and optimise molecular simulations.They provide speed and accuracy that were thought to be unachievable before [104]. More advanced drug discovery models are anticipated as AI continues to advance.There are plans to develop deep learning models that can more accurately predict drug-target interactions or mimic protein folding [125].A more comprehensive approach to drug design that takes complex biological systems into account will be possible with the integration of this enormous and diverse data into CADD, thanks to advancements in genomes, proteomics, and metabolomics [81].Standardising biological data to guarantee consistency and dependability in CADD approaches is becoming more difficult as the amount of data grows rapidly [126]. It is impossible to overlook the ecological impact of drug development. In order to ensure that medicine distribution does not result in environmental costs, future CADD models may need to include sustainability indicators [127]. Ethical worries regarding machine autonomy, transparency in algorithmic judgements, and possible biases are growing in importance as AI plays a bigger role in drug development [128]. Ultimately, the future of CADD is a complex web of ethical issues, difficulties, and creativity.CADD can continue to transform drug research and improve everyone's health by anticipating these issues and using emerging technology.

11. BridgingtheGap:IntegratingExperimentalDatawithCADD

ForgingSynergy:WhentheComputationalMeetstheExperimentalinDrugDesign

There is unmatched promise in the synergy of experimental biology and computational approaches in drug creation as the gap between them closes. Experimental data serves as both the basis and the validater of these predictions, even if CADD offers the means to forecast and simulate [129].Although CADD may predict a wide range of pharmacological qualities, they are just theoretical until they are confirmed by experimentation. Among other characteristics, experimental data provide proof of pharmacological effectiveness, metabolism, and safety [130]. Experimental data enhances CADD predictions in addition to validating them. When a predicted molecule does not produce the desired outcomes in the lab, these statistics are quite helpful.Later design iterations are informed by it, resulting in a more polished and probably successful candidate [131]. Simulations of molecular dynamics may forecast the long-term behaviour of molecules. However, snapshots of these molecules are obtained using experimental methods such as nuclear magnetic resonance (NMR) or X-ray crystallography, which may confirm or recalculate these simulations [132].A lot of data is provided by experimental findings from assays, high-throughput screens, and other techniques. AI and other CADD techniques may be used to mine this data in order to identify patterns, correlations, or possible medication candidates that would otherwise go unnoticed [133].The predictive models employed in CADD may be trained more efficiently with an expanding library of experimental outcomes.Over time, the precision of CADD models is continuously improved by this integration, increasing their dependability [134]. Real-world experimental data supplies the actual map, while CADD gives tools to help traverse the intricate web of biological systems.When combined, they provide a more direct route to promising therapeutic candidates [135]. Overall, the combination of CADD and experimental data is synergistic rather than just complimentary. Building closer ties across these areas makes drug discovery more reliable, effective, and precise.Developing Tomorrow's Drug Designers: The Significance of CADD in Contemporary Education

The promising field of drug development requires advanced technology and skilled brains to use it. The need of incorporating CADD training into modern schooling is highlighted by the fact that CADD is becoming a crucial component of the drug development landscape [136].

While conventional biology and chemistry curricula place a strong emphasis on fundamental knowledge, the introduction of CADD courses may provide students an early introduction to the computational components of drug creation. The next generation of drug discoverers may be cultivated and curiosity piqued by such basic exposure [137].Universities all around the globe are beginning to see the value of specialised courses that only cover CADD. These programs combine biology, drug pharmacology, and computational approaches to create professionals who can lead drug development initiatives [138].Because CADD is dynamic and ever-changing, professionals must always be learning. For experts to keep up to date on the most recent CADD approaches, workshops, online courses, and conferences are essential [139].

Drug design is a symphony of many different fields. It is essential to make sure that CADD training incorporates aspects of biology, chemistry, artificial intelligence, and even ethics rather than being isolated. Professionals with a diversified, holistic approach are well-rounded [140].It is encouraging to see that several universities provide postgraduate and early-career scientists with research opportunities centred on CADD. These platforms bridge the gap between theoretical and practical applications by enabling hands-on experience [141]. The competence of CADD specialists is of relevance to the biotech and pharmaceutical sectors. Curriculum development may be guided by industry-academia collaboration to make sure it meets the practical needs of drug discovery [142].In conclusion, educating competent workers becomes crucial as the drug discovery tower focusses more on CADD. A better, healthier future is what an investment in education represents.

12. TheFutureOutlook:CADDsTrajectoryandUpcomingChallenges

Given the speed at which CADD is developing and its crucial role in recent drug discoveries, we are prompted to consider the future of this field and the difficulties it faces [143]. Quantum computers have a huge potential influence on CADD as they get closer to being used in real-world scenarios. Drug development may be greatly accelerated by using quantum algorithms, which can significantly cut down on the amount of time needed for molecular simulations [104]. Even if machine learning and artificial intelligence have already established themselves in CADD, the development of deep learning models has the potential for even more accurate forecasts. These models, trained on large datasets, may ultimately outperform conventional simulation techniques in terms of accuracy [144].Once thought to be "undruggable," targets are now in the sights of CADD due to biological advancements. This change necessitates that CAD develop and invent techniques to interact with these difficult targets [145].As CADD and AI models begin to play a larger role in assessing drug viability, ethical concerns around reliability, bias in forecasts, and accountability will surface. Resolving these issues will be crucial [146].With the abundance of biological data provided by proteomics, metabolomics, and genomes, CADDs will likely continue to use this data inefficiently. Better drug design may be facilitated by integrating multi-omics data, which can provide a comprehensive perspective of biological systems [147]. Furthermore, high-specification hardware is required for the execution of various simulation processes in AI/ML, in addition to large datasets. Strong hardware configurations with strong CPUs, plenty of memory, and effective GPUs are necessary to meet the computational needs of AI/ML algorithms, such deep learning models. In order to optimise the training and inference stages of AI/ML systems and guarantee the prompt and correct processing of tasks, access to high-performance hardware is essential.

Ensuring the privacy and security of shared data becomes more important as collaborative initiatives grow more widespread.It will be crucial to create standards and methods for data exchange without sacrificing security [148].It is impossible to overlook the environmental impact of drug development, particularly when using computational techniques that need a lot of energy. Future CADD approaches need to take environmental effect and medication efficacy into account [149].In summary, while CADD has a bright future, there are obstacles to overcome. It will need a combination of technical expertise, moral awareness, and a dedication to sustainable practices to successfully navigate this maze.

13. CollaborativeEffortsandGlobalInitiativesinCADD

BridgingBoundaries:HowGlobalCollaborationsAreAmplifyingtheImpactofCADD

Drug development presents enormous obstacles that often exceed the capabilities of certain organisations or countries.A wave of international initiatives and cooperative efforts in CADD have been formed in recognition of this, combining resources, knowledge, and data for a shared objective [150].Platforms like OpenZika and Open-Source Malaria are leading the way in democratising drug research. By making research data and tools publicly accessible, these platforms encourage broad engagement and creativity [151]. Academic institutions, businesses, and nonprofit organisations come together via collaborative groupings like the Structural Genomics Consortium and the Innovative Medicines Initiative (IMI). Consortia like this expedite research, avoid duplication, and speed up discovery [152]. It is impossible to overestimate the importance of exchanging molecular datasets, software tools, and algorithms. Projects such as the Protein Data Bank, ChemSpider, and PubChem are repositories that are very helpful to researchers worldwide [153].
Small research teams may conduct large-scale simulations without making enormous equipment expenditures thanks to cloud systems like IBM's Watson for Drug Discovery, which share computing resources [154]. Prominent institutions often participate in cooperative research initiatives, reaping the benefits of pooled resources, experience, and varied viewpoints. These kinds of partnerships result in ground-breaking CADD inventions and discoveries [155]. Although partnerships provide many advantages, there are drawbacks as well.Concerns over intellectual property rights, data privacy, and disparate regulatory requirements mightbe obstacles.Thorough planning and strong legal structures are necessary to address these issues [156]. Even if the road to successful drug development is long, teamwork promises to shorten and improve the process. The most difficult obstacles in CADD will be overcome with teamwork.

14. CADD in Personalized Medicine: Tailoring Therapiesto Individuals

Often used interchangeably with precision medicine, personalised medicine aims to customise treatment by adjusting procedures and choices for each patient. Treatment paradigms might be revolutionised by combining CADD with personalised medicine [157]. A comprehensive genetic blueprint has been made available by the Human Genome Project's completion. Using this knowledge, CADD may assist in the development of medications that target certain genetic mutations or variations linked to illnesses [158]. Through the integration of proteomic, genomic, and epigenetic data, CADD systems are able to predict how a patient would likely react to a medication.This reduces side effects and makes it easier to provide treatments that are probably effective [159].In some rare illnesses brought on by specific genetic abnormalities, CAD presents the potential for the development of medications specifically designed for each patient, which would be the ultimate in personalised treatment. Because they provide quantifiable indications of illness states, biomarkers are essential in personalised medicine.CADD assists in the identification of medications that may alter these biomarkers, resulting in individualised treatment plans.With the increasing use of electronic health records, combining this real-world data with CADD models may provide information on how well drugs work in certain populations, enabling more tailored treatment recommendations.
Although the promise for personalised medicine via CADD is intriguing, there are ethical concerns, particularly with respect to data privacy and possible disparities in access to customised therapies. In conclusion, the convergence of personalised medicine and CADD offers therapies tailored to each patient, going beyond the one-size-fits-all strategy.Using computational technologies in conjunction with personal data will usher in a new age of healthcare.
This method, which is sometimes referred to as theranostics, uses CADD to create medications in addition to diagnostic tests that

assess a patient's appropriateness for therapy.This guarantees that the patient receives the appropriate medication at the appropriate time.Patient-derived models, such as organoids or patient-derived xenografts, significantly improve personalised therapy.CADD can simulate drug reactions using data from these models, enabling customised treatment modifications [160].Given the variability of tumours, even within the same cancer type, cancer epitomises the need for personalised therapy. Tumour genomic data may be analysed by CADD techniques to find druggable targets specific to each patient's cancer profile [161]. As wearable technology advances, it will be possible to improve medication recommendations based on current patient condition by gathering a variety of health measurements and combining them with CADD models [162]. The expenses involved remain a worry, notwithstanding the revolutionary potential of CADD-driven personalised treatment.A critical difficulty is making sure that these customised therapies are both affordable and available to everyone, regardless of socioeconomic background [163]. Redefining treatment plans and guaranteeing that patients get therapies catered to their individual genetic and physiological profiles might be achieved by combining CADD with personalised medicine. However, like with any revolutionary developments, it is still crucial to strike a balance between creativity, ethics, cost, and accessibility.

15. Elevating Drug Design: The Convergence of AI, Machine Learning, and CADD

Machine learning (ML) and artificial intelligence (AI) have lately gained significant traction in a number of scientific fields. Drug discovery procedures are undergoing revolutionary changes as a result of their interaction with computer-aided drug design, or CADD [164].

Deep learning, which is a subset of machine learning, has shown adept in predicting therapeutic characteristics, analysing molecular structures, and optimising molecular design, particularly when combined with convolutional neural networks (CNNs) [165]. Drug-drug interactions may be predicted by AI-driven models, which provide insights into possible synergy or bad responses when Co-administration of many medications occurs [134]. AI models have been crucial in discovering novel therapeutic uses for already-approved medications by analysing enormous datasets of pharmacological characteristics and clinical results [166]. By permitting more precise predictions of a molecule's biological activity based on its chemical structure, quantitative structure-activity relationship (QSAR) models gain from machine learning [167]. AI can speed up high-throughput screening of large molecular libraries, reducing the time needed for conventional approaches to identify possible drug candidates [168]. AI may help create new therapeutic molecules from the ground up, modifying them to have the necessary qualities while reducing the possibility of adverse consequences [169]. Although AI and ML provide promising opportunities in CADD, they are not without difficulties.Concerns include interpretability, overfitting, data quality, and the need for significant computing resources [66]. To sum up, drug discovery is changing as a result of AI and ML. With the combination of these technologies' computational power and the methodological rigour of CADD, the promise of safer, more effective, and customised medications seems closer than ever.

16. Conclusions

In summary, computer-aided drug design is a revolutionary catalyst in contemporary drug discovery, situated at the nexus of computational power and biological complexity. Its crucial importance in accelerating drug development is shown by the route from past discoveries to the current environment.But as CADD charts its course, problems arise that need for ongoing optimisation, moral considerations, and the blending of various biological facts. The concrete effects of CADD on clinical applications are shown by success stories, and the use of machine learning enhances predictive skills and opens up new possibilities.Global efforts and collaborative networks democratise drug development by highlighting the power of unity.Although there are accessibility and ethical issues, the convergence of personalised medicine provides customised remedies.Future developments in quantum computing, immersive technologies, and green chemistry offer a paradigm change that necessitates a careful balancing act between creativity and moral obligation. Open-source projects and collaborative platforms emphasise shared knowledge in a global setting, acting as rays of optimism. CADD's responsible progress is heavily influenced by ethical and legal issues, particularly as it integrates with new technology and negotiates the challenges of the digital age. Drug development is enhanced by the symbiotic interaction between experimental data and CADD, which emphasises the complementary nature of computational predictions and empirical validations. CADD training must be included into school in order to develop competent people who can successfully navigate the complex field of drug development. Since CADD foresees issues with sustainability, bias reduction, and accuracy, preemptive steps must be made to guarantee appropriate and legal usage.CADD's trajectory is essentially one of innovation, obstacles, and ethical issues, setting the stage for a future in which drug development is more rapid, accurate, and patient-centered, eventually leading to a healthier future.

References

1. Johnson,A.M.;Smith,B.C.Historicalperspectivesindrugdiscovery:Theadventofcomputationaltools.*J. Drug Discov.***1995**,*12*,5–15.
2. Patel,Y.;Chalmers,D.K.Modelingdrug-receptorinteractions:Advancesandchallenges.*J.Med.Chem.***2003**,*46*,2543–2554.
3. Green, P.L.; Edwards, P.H. Structural biology and computational chemistry:A symbiotic relationship.*Chem.Rev.***2010**, *110*, 5678–5698.
4. Walker,N.T.;Williams,J.P.Zanamivir:Themakingofadrug.*Nat.Biotechnol.***1997**,*15*,232–235.
5. Martinez,A.Computationalstrategiesindrugdesign.*DrugDiscov.Today***2006**,*11*,149–155.
6. CCBY4.0Deed/Attribution4.0International/CreativeCommons(n.d.).Availableonline:https://creativecommons.org/licenses/by/4.0/(accessed on 10 November 2023).
7. Lu,W.;Zhang,R.;Jiang,H.;Zhang,H.;Luo,C.Computer-Aideddrugdesigninepigenetics.*Front.Chem.* **2018b**,*6*,57.[CrossRef] [PubMed]
8. Kapoor,L.;Oprea,T.I.Fromempiricaltorationaldrugdiscovery:TheimportanceofCADD.*DrugDes.Rev.***2018**,*15*,345–356.
9. Fu,C.;Xiang,M.A.;Chen,S.;Dong,G.;Liu,Z.;Chen,C.;Liang,J.;Cao,Y.;Zhang,M.;Liu,Q.Moleculardrugsimulation and experimental validation of the CD36 receptor competitively binding to Long-Chain fatty acids by 7-Ketocholesteryl-9-carboxynonanoate.*ACS Omega* **2023**, *8*, 28277–28289. [CrossRef]
10. Schaduangrat,N.;Lampa,S.;Simeon,S.;Gleeson,M.P.;Spjuth,O.;Nantasenamat,C.Towardsreproduciblecomputationaldrug discovery. *J. Cheminform.* **2020**, *12*, 9. [CrossRef]
11. Thompson,M.A.TechniquesinComputer-AidedDrugDesign.*BioorganicMed.Chem.***2004**,*12*,3101–3110.
12. Lipinski,C.A.;Lombardo,F.;Dominy,B.W.;Feeney,P.J.Experimentalandcomputationalapproachestoestimatesolubilityand permeabilityindrugdiscoveryanddevelopmentsettings. *Adv. DrugDeliv. Rev.* **1997**,*23*,3–25. [CrossRef]
13. ERC. Computational Biology: Spotlight on ERC projects. Available online: https://erc.europa.eu/projects-statistics/science-stories/computational-biology-spotlight-erc-projects(accessedon27November2023).
14. Leach,A.R.;Gillet,V.J.Molecularmodeling:Principlesandapplications.*J.Chem.Inf.Model.* **2007**,*47*,5–27.
15. Jumper, J.;Evans,R.;Pritzel,A.;Green,T.;Figurnov,M.;Ronneberger,O.;Tunyasuvunakool,K.;Bates,R.;Žídek,A.;Potapenko, A.; et al. Highly accurate protein structure prediction with AlphaFold. *Nature***2021**, *596*, 583–589. [CrossRef] [PubMed]
16. Yang, J.; Anishchenko, I.; Park, H.; Peng, Z.; Ovchinnikov, S.; Baker, D. Improved protein structure prediction using predicted interresidueorientations.*Proc.Natl.Acad.Sci.USA***2020**,*117*,1496–1503.[CrossRef][PubMed]
17. Du, Z.; Su, H.; Wang, W.; Ye, L.; Wei, H.; Peng, Z.; Anishchenko, I.; Baker, D.; Yang, J. The trRosetta server for fast and accurate proteinstructureprediction.*Nat.Protoc.***2021**,*16*,5634–5651.[CrossRef][PubMed]
18. Kim,D.E.;Chivian,D.;Baker,D.Proteinstructurepredictionandanalysisusingthe Robettaserver.*NucleicAcidsRes.***2004**,*32*, W526–W531.[CrossRef][PubMed]
19. Baek,M.;DiMaio,F.;Anishchenko,I.;Dauparas,J.;Ovchinnikov,S.;Lee,G.R.;Wang,J.;Cong,Q.;Kinch,L.N.;Schaeffer,R.D.; etal.Accuratepredictionofproteinstructuresandinteractionsusingathree-trackneuralnetwork.*Science***2021**,*373*,871–876. [CrossRef]
20. Lin, Z.; Akin, H.; Rao, R.; Hie, B.; Zhu, Z.; Lu, W.; Smetanin, N.; Verkuil, R.; Kabeli, O.; Shmueli, Y.; et al. Language models of proteinsequencesatthescaleofevolutionenableaccuratestructureprediction.*bioRxiv***2022**,*2020*,500902.[CrossRef]
21. Wu, R.; Ding, F.; Wang, R.; Shen, R.; Zhang, X.; Luo, S.; Su, C.; Wu, Z.; Xie, Q.; Berger, B.; et al. High-resolution de novo structureprediction from primary sequence. *bioRxiv* **2022**. [CrossRef]
22. Niazi,S.K.;Mariam,Z.ReinventingTherapeuticProteins:Miningatreasureofnewtherapies.*Biologics***2023**,*3*,72–94.[CrossRef]
23. Berendsen, H.J.C.; Van Der Spoel, D.; Van Drunen, R. GROMACS: A message-passing parallel molecular dynamics implementation.*Comput. Phys. Commun.* **1995**,*91*,43–56. [CrossRef]
24. Harvey, M.;Giupponi,G.;DeFabritiis,G.ACEMD:AcceleratingBiomolecularDynamicsintheMicrosecondTimeScale. *J.Chem. TheoryComput.***2009**,*5*,1632–1639. [CrossRef][PubMed]
25. Eastman, P.; Swails, J.; Chodera, J.D.; McGibbon, R.T.; Zhao, Y.; Beauchamp, K.A.; Wang, L.; Simmonett, A.C.; Harrigan, M.P.; Stern, C.; et al. OpenMM 7: Rapid development of high performance algorithms for molecular dynamics.*PLoS Comput. Biol.* **2017**, *13*, e1005659. [CrossRef] [PubMed]
26. Adcock,S.A.;McCammon,J.A.Moleculardynamics:Surveyofmethodsforsimulatingtheactivityofproteins.*Chem.Rev.***2006**, *106*,1589–1615.[CrossRef][PubMed]
27. Morris,G.M.;Lim-Wilby,M.Moleculardocking.*MethodsMol.Biol.***2008**,*443*,365–382.[PubMed]
28. Trott,O.;Olson,A.J.AutoDockVina:Improvingthespeedandaccuracyofdockingwithanewscoringfunction,efficient optimization,andmultithreading. *J.Comput. Chem.* **2010**,*31*,455–461. [CrossRef][PubMed]
29. Morris,G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4:Automateddockingwithselectivereceptorflexibility. *J.Comput.Chem.***2009**,*30*,2785–2791. [CrossRef][PubMed]
30. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Shenkin, P.S. Glide:A new approach for rapid,accuratedockingandscoring. 1. Methodandassessmentofdockingaccuracy. *J.Med.Chem.***2004**,*47*,1739–1749. [CrossRef]
31. Ewing, T.J.A.; Makino, S.; Skillman, A.G.; Kuntz, I.D. DOCK 4.0:Search strategies for automated molecular docking of flexible moleculedatabases. *J.Comput.AidedMol.Des.***2001**,*15*,411–428. [CrossRef]

32. Venkatachalam, C.M.; Jiang, X.; Oldfield, T.; Waldman, M. LigandFit:A novel method for the shape-directed rapid docking of ligandstoproteinactivesites. *J.Mol.Graph.Model.***2003**,*21*,289–307. [CrossRef]
33. Bitencourt-Ferreira,G.;DeAzevedo,W.F.DockingwithSwissDock.*MethodsMol.Biol.***2019**,*2053*,189–202.[CrossRef][PubMed]
34. Willett,P.Virtualscreeningusingmoleculardocking.*DrugDiscov.TodayTechnol.***2006**,*3*,229–234.
35. Karatzas, E.; Zamora, J.E.; Athanasiadis, E.; Dellis, D.; Cournia, Z.; Spyrou, G.M. ChemBioServer 2.0: An advanced web server forfiltering,clusteringandnetworkingofchemicalcompoundsfacilitatingbothdrugdiscoveryandrepurposing.*Bioinformatics* **2020**, *36*, 2602–2604. [CrossRef] [PubMed]
36. Pinzi,L.;Rastelli,G.Moleculardocking:Shiftingparadigmsindrugdiscovery.*Int.J.Mol.Sci.***2019**,*20*,4331.[CrossRef] [PubMed]
37. Sahoo,R.N.;Pattanaik,S.;Pattnaik,G.;Mallick,S.;Mohapatra,R.ReviewontheuseofMolecularDockingastheFirstLineTool inDrugDiscoveryandDevelopment. *IndianJ.Pharm. Sci.* **2022**,*84*,1334–1337. [CrossRef]
38. Hansch,C.;Leo,A.*ExploringQSAR:Hydrophobic,Electronic,andStericConstants*;ACSProfessionalReferenceBook:Washington, DC,USA,1995.
39. Niazi, S.K.; Mariam, Z. Recent Advances in Machine-Learning-Based Chemoinformatics: A Comprehensive Review. *Int. J.Mol. Sci.***2023**, *24*, 11488. [CrossRef] [PubMed]
40. Luo,M.;Wang,X.S.;Tropsha,A.ComparativeAnalysisofQSAR-basedvs.ChemicalSimilarityBasedPredictorsofGPCRs Binding Affinity. *Mol. Inform.* **2016**, *35*, 36–41. [CrossRef]
41. Raj, N.; Jain, S.K. 3d QSAR studies in conjunction with k-nearest neighbor molecular field analysis (k-NN-MFA) on a series of substituted 2-phenyl-benzimidazole derivatives as an anti allergic agents.*Dig. J.Nanomater. Biostructures***2011**, *6*, 1811–1821.
42. Nigsch,F.;Bender,A.;vanBuuren,B.;Tissen,J.;Nigsch,E.;Mitchell,J.B.Meltingpointpredictionemployingk-nearestneighbor algorithmsandgeneticparameteroptimization. *J.Chem.Inf.Model.***2006**,*46*,2412–2422. [CrossRef]
43. Güner,O.F.Pharmacophoreperception,development,anduseindrugdesign.*J.Med.Chem.***2002**,*45*,5–12.
44. Zhang, Y.; Yang, S.; Jiao, Y.; Liu, H.; Yuan, H.; Lü, S.; Ran, T.; Yao, S.; Ke, Z.; Xu, J.; et al. An integrated virtual screening approach forVEGFR-2inhibitors. *J.Chem. Inf. Model.* **2013**,*53*,3163–3177. [CrossRef][PubMed]
45. Fidom, K.; Ísberg, V.; Hauser, A.S.; Mordalski, S.; Lehto, T.; Bojarski, A.J.; Gloriam, D.E. A new crystal structure fragment-based pharmacophoremethodforGprotein-coupledreceptors. *Methods***2015**,*71*,104–112. [CrossRef][PubMed]
46. Munk, C.; Harpsøe, K.; Hauser, A.S.; Isberg, V.; Gloriam, D.E. Integrating structural and mutagenesis data to elucidate GPCRligand binding. *Curr. Opin. Pharmacol.* **2016**, *30*, 51–58. [CrossRef] [PubMed]
47. Ekins,S.;Williams,A.J.Insilicopharmacokinetics:ADMEindrugdiscovery.*DrugDiscov.World***2007**,*8*,17–24.
48. Schneider, G.; Fechner, U. Computer-based de novo design of drug-like molecules.*Nat.Rev.Drug Discov.***2005**, *4*, 649–663. [CrossRef] [PubMed]
49. Zhang,L.;Tan,J.AIanditsroleindrugdiscovery.*J.DrugDiscov.Des.***2019**,*5*,1–10.
50. Bishop,C.M.*PatternRecognitionandMachineLearning*;Springer:Berlin/Heidelberg,Germany,2006.
51. Goh,G.B.;Hodas,N.O.;Vishnu,A.Deeplearningforcomputationalchemistry.*J.Comput.Chem.***2017**,*38*,1291–1307.[CrossRef]
52. Vilar, S.; Uriarte, E.; Santana, L.; Lorberbaum, T.; Hripcsak, G. Predicting drug-drug interactions through drug structural similaritiesandinteractionnetworksincorporatingpharmacokineticsandpharmacodynamicsknowledge. *J.Cheminformatics* **2016**, *8*, 12.
53. Aliper, A.; Plis, S.; Artemov, A.; Ulloa, A.; Mamoshina, P.; Zhavoronkov, A. Deep learning applications for predicting pharmacological propertiesofdrugsanddrugrepurposingusingtranscriptomicdata.*Mol.Pharm.***2016**,*13*,2524–2530.[CrossRef]
54. Kadurin,A.;Aliper,A.;Kazennov,A.;Mamoshina,P.;Vanhaelen,Q.;Khrabrov,K.;Zhavoronkov,A.Thecornucopiaofmeaningful leads: Applyingdeepadversarialautoencodersfornewmoleculedevelopmentinoncology.*Oncotarget***2017**,*8*,10883–10890. [CrossRef]
55. Mayr, A.;Klambauer,G.;Unterthiner,T.;Hochreiter,S.DeepTox:Toxicitypredictionusingdeeplearning.*Front.Environ.Sci.* **2016**,*3*,80.[CrossRef]
56. Chen,H.;Engkvist,O.;Wang,Y.;Olivecrona,M.;Blaschke,T.Theriseofdeeplearningindrugdiscovery.*DrugDiscov.Today* **2018**,*23*,1241–1250.[CrossRef][PubMed]
57. Jorgensen,W.L.Themanyrolesofcomputationindrugdiscovery.*Science***2004**,*303*,1813–1818.[CrossRef][PubMed]
58. Warren,G.L.;Andrews,C.W.;Capelli,A.M.;Clarke,B.;LaLonde,J.;Lambert,M.H.;Murray,C.W.Acriticalassessmentofdocking programsandscoringfunctions. *J.Med.Chem.***2006**,*49*,5912–5931. [CrossRef][PubMed]
59. Aleksandrova, A. Machine-Learning Scoring Functions to Improve Structure-Based Binding Affinity Prediction and Virtual Screening. 2016. Availableonline: https://www.academia.edu/28830051/Machine_learning_scoring_functions_to_improve_structure_based_binding_affinity_prediction_and_virtual_screening(accessed on 10 November 2023).
60. Fujimoto, K.; Minami, S.; Yanai, T. Machine-Learning- and Knowledge-Based scoring functions incorporating ligand and proteinfingerprints.*ACS Omega* **2022**, *7*, 19030–19039. [CrossRef] [PubMed]
61. Guedes, I.A.; Barreto, A.; Marinho, D.; Krempser, E.; Kuenemann, M.A.; Spérandio, O.; Dardenne, L.E.; Miteva, M.A. New machinelearningandphysics-basedscoringfunctionsfordrugdiscovery. *Sci. Rep.* **2021**,*11*,3198. [CrossRef]
62. Walters,W.P.;Murcko,M.A.Predictionof'drug-likeness'.*Adv. DrugDeliv. Rev.***2002**,*54*,255–271.[CrossRef]
63. Kitchen, D.B.; Decornez, H.; Furr, J.R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: Methods and applications. *Nat.Rev.DrugDiscov.***2004**,*3*,935–949. [CrossRef]

64. Dror, R.O.; Dirks, R.M.; Grossman, J.P.; Xu, H.; Shaw, D.E. Biomolecular simulation: A computational microscope for molecular biology. *Annu.Rev.Biophys.***2012**,*41*,429–452. [CrossRef]
65. Teague,S.J.Implicationsofproteinflexibilityfordrugdiscovery.*Nat.Rev.DrugDiscov.***2003**,*2*,527–541.[CrossRef]
66. Ching,T.;Himmelstein,D.S.;Beaulieu-Jones,B.K.;Kalinin,A.A.;Do,B.T.;Way,G.P.;Greene,C.S.Opportunitiesandobstaclesfordeep learning in biology and medicine.*J. R. Soc.Interface* **2018**, *15*, 20170387.[CrossRef] [PubMed]
67. Bajorath,J.Integrationofvirtualandhigh-throughputscreening.*Nat.Rev.DrugDiscov.***2012**,*1*,882–894.[CrossRef][PubMed]
68. Shoichet,B.K.Virtualscreeningofchemicallibraries.*Nature***2004**,*432*,862–865.[CrossRef][PubMed]
69. Macarron,R.;Banks,M.N.;Bojanic,D.;Burns,D.J.;Cirovic,D.A.;Garyantes,T.;Hertzberg,R.P.Impactofhigh-throughput screeninginbiomedicalresearch.*Nat.Rev.DrugDiscov.***2011**,*10*,188–195.[CrossRef][PubMed]
70. Zhang,J.H.;Chung,T.D.;Oldenburg,K.R.Asimplestatisticalparameterforuseinevaluationandvalidationofhighthroughput screeningassays. *J.Biomol. Screen.* **1999**,*4*,67–73. [CrossRef][PubMed]
71. Pound, P.;Bracken,M.B.Isanimalresearchsufficientlyevidence-basedtobeacornerstoneofbiomedicalresearch?*BMJ* **2014**, *348*, g3387.[CrossRef][PubMed]
72. Blundell,T.L.Proteincrystallographyanddrugdiscovery:Recollectionsofknowledgeexchangebetweenacademiaandindustry. *IUCrJ***2017**,*4*,308–321. [CrossRef]
73. Sterling,T.;Irwin,J.J.ZINC15—Liganddiscoveryforeveryone.*J.Chem.Inf.Model.***2015**,*55*,2324–2337.[CrossRef]
74. Schneider,G.Automatingdrugdiscovery.*Nat.Rev.DrugDiscov.***2018**,*17*,97–113.[CrossRef]
75. Vamathevan, J.; Clark, D.; Czodrowski, P.; Dunham, I.; Ferran, E.; Lee, G.; Puhl, A.C. Applications of machine learning in drugdiscoveryanddevelopment. *Nat.Rev.DrugDiscov.***2019**,*18*,463–477. [CrossRef]
76. Qureshi, R.; Irfan, M.; Gondal, T.M.; Khan, S.; Wu, J.; Hadi, M.U.; Heymach, J.; Le, X.; Yan, H.; Alam, T. AI in drug discovery andits clinical relevance. *Heliyon***2023**, *9*, e17575. [CrossRef] [PubMed]
77. Zhang, L.; Tan, J.; Han, D.; Zhu, H. From machine learning to deep learning: Progress in machine intelligence for rational drug discovery.*DrugDiscov.Today***2017**,*22*,1680–1685.[CrossRef][PubMed]
78. Le, W.T.; Maleki, F.; Romero, F.P.; Forghani, R.; Kadoury, S. Overview of Machine Learning: Part 2: Deep Learning for Medical ImageAnalysis. *NeuroimagingClin. N.Am.* **2020**,*30*,417–431. [CrossRef][PubMed]
79. Walters,W.P.;Murcko,M.AssessingtheimpactofgenerativeAIonmedicinalchemistry.*Nat.Biotechnol.***2020**,*38*,143–145. [CrossRef][PubMed]
80. Topol,E.J.High-performancemedicine:Theconvergenceofhumanandartificialintelligence.*Nat.Med.***2019**,*25*,44–56. [CrossRef] [PubMed]
81. Hasin,Y.;Seldin,M.;Lusis,A.Multi-omicsapproachestodisease.*GenomeBiol.***2017**,*18*,83.[CrossRef][PubMed]
82. Nicholson,J.K.;Lindon,J.C.Systemsbiology:Metabonomics.*Nature***2008**,*455*,1054–1056. [CrossRef]
83. Zhang,W.;Chien,J.;Yong,J.;Kuang,R.Network-basedmachinelearningandgraphtheoryalgorithmsforprecisiononcology. *NPJPrecis.Oncol.***2017**,*1*,25.[CrossRef]
84. Subramanian,I.;Verma,S.;Kumar,S.;Jere,A.;Anamika,K.Multi-omicsDataIntegration,Interpretation,andItsApplication. *Bioinform.Biol.Insights***2020**,*14*,1177932219899051.[CrossRef]
85. Kim,M.S.;Pinto,S.M.;Getnet,D.;Nirujogi,R.S.;Manda,S.S.;Chaerkady,R.;Prasad,T.S.K.Adraftmapofthehumanproteome. *Nature***2014**,*509*,575–581. [CrossRef]
86. Wishart, D.S. Emerging applications of metabolomics in drug discovery and precision medicine. *Nat. Rev. Drug Discov.* **2016**, *15*,473–484. [CrossRef] [PubMed]
87. Barabási,A.L.;Gulbahce,N.;Loscalzo,J.Networkmedicine:Anetwork-basedapproachtohumandisease.*Nat.Rev.Genet.***2011**, *12*,56–68.[CrossRef][PubMed]
88. Williams, A.J.; Harland, L.; Groth, P.; Pettifer, S.; Chichester, C.; Willighagen, E.L.; Goble, C. Open PHACTS: Semantic interoperabilityfordrugdiscovery.*DrugDiscov.Today***2012**,*17*,1188–1198.[CrossRef][PubMed]
89. Cournia, Z.; Allen, B.; Sherman, W. Relative binding free energy calculations in drug discovery: Recent advances and practicalconsiderations.*J. Chem. Inf. Model.* **2017**, *57*, 2911–2937. [CrossRef] [PubMed]
90. Gayathiri, E.; Prakash, P.; Kumaravel, P.; Jayaprakash, J.; Ragunathan, M.G.; Sankar, S.; Pandiaraj, S.; Thirumalaivasan, N.; Thiruvengadam,M.;Govindasamy,R.Computationalapproachesformodelingandstructuraldesignofbiologicalsystems: Acomprehensivereview. *Prog. Biophys. Mol. Biol.* **2023**,*185*,17–32. [CrossRef][PubMed]
91. Sastry,G.M.;Adzhigirey,M.;Day,T.;Annabhimoju,R.;Sherman,W.Proteinandligandpreparation: Parameters,protocols,and influenceonvirtualscreeningenrichments. *J.Comput.AidedMol.Des.***2013**,*27*,221–234. [CrossRef]
92. Meng, X.Y.; Zhang, H.X.; Mezei, M.; Cui, M. Molecular docking: A powerful approach for structure-based drug discovery. *Curr. Comput.AidedDrugDes.***2011**,*7*,146–157. [CrossRef]
93. Mascalzoni,D.;Dove,E.S.;Rubinstein,Y.;Dawkins,H.J.;Kole,A.;McCormack,P.;Woods,S.InternationalCharterofprinciplesfor sharing bio-specimens and data.*Eur. J. Hum. Genet.* **2014**, *23*, 721–728.[CrossRef]
94. Bassani,D.;Moro,S.Past,Present,andFuturePerspectivesonComputer-AidedDrugDesignMethodologies.*Molecules***2023**,*28*, 3906.[CrossRef]
95. Wlodawer, A.;Vondrasek,J.InhibitorsofHIV-1protease: Amajorsuccessofstructure-assisteddrugdesign.*Annu. Rev. Biophys. Biomol. Struct.* **1998**,*27*,249–284. [CrossRef]

96. von Itzstein, M. The war against influenza: Discovery and development of sialidase inhibitors. *Nat. Rev. DrugDiscov.* **2007**, *6*, 967–974. [CrossRef] [PubMed]
97. Deininger,M.W.N.;Druker,B.J.Specifictargetedtherapyofchronicmyelogenousleukemiawithimatinib.*Pharmacol.Rev.***2003**, *55*,401–423.[CrossRef][PubMed]
98. Harper,S.;McCauley,J.A.;Rudd,M.T.Recentadvancesinthediscoveryofsmallmoleculeinhibitorsofhepatitis Cvirus.*Annu. Rev. Pharmacol. Toxicol.* **2014**, *54*, 317–338.
99. Ghosh, A.K.; Brindisi, M.; Tang, J. Developing β-secretase inhibitors for treatment of Alzheimer's disease. *J. Neurochem.* **2012**, *120*, 71–83. [CrossRef] [PubMed]
100. Mintun, M.A.; Lo, A.; Evans, C.; Wessels, A.M.; Ardayfio, P.; Andersen, S.W.; Shcherbinin, S.; Sparks, J.; Sims, J.R.; Brys´, M.; et al. DonanemabinearlyAlzheimer'sdisease. *N.Engl. J.Med.* **2021**,*384*,1691–1704. [CrossRef][PubMed]
101. Doody,R.R.S.;Thomas,R.R.G.R.;Farlow,M.R.;Iwatsubo,T.;Vellas,B.;Joffe,S.;Kieburtz,K.;Raman,R.;Sun,X.;Aisen,P.S.; etal. Phase3trialsofSolanezumabforMild-to-ModerateAlzheimer'sDisease. *N.Engl.J.Med.***2014**,*370*,311–321. [CrossRef] [PubMed]
102. Rani, I.; Kalsi, A.; Kaur, G.; Sharma, P.; Gupta, S.; Gautam, R.K.; Chopra, H.; Bibi, S.; Ahmad, S.U.; Singh, I.; et al. Modern drug discovery applications for the identification of novel candidates for COVID-19 infections.*Ann. Med. Surg.***2022**, *80*, 104125. [CrossRef]
103. Amir, S.; Arathi, A.; Reshma, S.; Mohanan, P.V. Microfluidic devices for the detection of disease-specific proteins and other macromolecules,diseasemodellinganddrugdevelopment: Areview. *Int.J.Biol.Macromol.***2023**,*235*,123784. [CrossRef]
104. Cao, Y.; Romero, J.; Olson, J.P.; Degroote, M.; Johnson, P.D.; Kieferová, M.; Aspuru-Guzik, A. Quantum chemistry in the age of quantumcomputing. *Chem.Rev.***2019**,*119*,10856–10915. [CrossRef]
105. O'Connor, M.; Deeks, H.M.; Dawn, E.; Metatla, O.; Roudaut, A.; Sutton, M.; Glowacki, D.R. Sampling molecular conformations anddynamicsinamulti-uservirtualrealityframework. *Sci. Adv.* **2018**,*4*,eaat2731. [CrossRef]
106. Ryan, D.K.; Maclean, R.H.; Balston, A.; Scourfield, A.; Shah, A.D.; Ross, J. Artificial intelligence and machine learning for clinical pharmacology. *Br. J.Clin. Pharmacol.* **2023**. [CrossRef] [PubMed]
107. Collins,F.S.;Varmus,H.Anewinitiativeonprecisionmedicine.*N.Engl.J.Med.***2015**,*372*,793–795.[CrossRef][PubMed]
108. Kanza, S.; Frey, J.G. A new wave of innovation in Semantic web tools for drug discovery.*Expert Opin.Drug Discov.***2019**, *14*, 433–444. [CrossRef] [PubMed]
109. Anastas,P.;Eghbali,N.Greenchemistry:Principlesandpractice.*Chem.Soc.Rev.***2010**,*39*,301–312.[CrossRef][PubMed]
110. Woelfle,M.;Olliaro,P.;Todd,M.H.Openscienceisaresearchaccelerator.*Nat.Chem.***2011**,*3*,745–748.[CrossRef][PubMed]
111. Morgera,E.;Tsioumani,E.;Buck,M.*UnravelingtheNagoyaProtocol:AcommentaryontheNagoyaProtocolonAccessandBenefit-SharingtotheConventiononBiologicalDiversity*;Brill: Leiden,TheNetherlands,2014.
112. Bhardwaj, A.; Scaria, V.; Raghava, G.P.; Lynn, A.M.; Chandra, N.; Banerjee, S.; Open Source Drug Discovery Consortium. Open source drug discovery—A new paradigm of collaborative research in tuberculosis drug development.*Tuberculosis* **2011**, *91*, 479–486. [CrossRef] [PubMed]
113. Ranard,B.L.;Ha,Y.P.;Meisel,Z.F.;Asch,D.A.;Hill,S.S.;Becker,L.B.;Merchant,R.M.Crowdsourcing—Harnessingthemassesto advancehealthandmedicine,asystematicreview. *J.Gen.Intern.Med.***2014**,*29*,187–203. [CrossRef]
114. Warr,W.A.Scientificworkflowsystems:PipelinePilotandKNIME.*J.Comput.AidedMol.Des.***2012**,*26*,801–804.[CrossRef]
115. McKiernan,E.C.;Bourne,P.E.;Brown,C.T.;Buck,S.;Kenall,A.;Lin,J.;Spies,J.R.Howopensciencehelpsresearcherssucceed. *eLife***2016**,*5*,e16800.[CrossRef]
116. Mons, B.; Neylon, C.; Velterop, J.; Dumontier, M.; da Silva Santos, L.O.B.; Wilkinson, M.D. Cloudy, increasingly FAIR: Revisiting the FAIR Data guiding principles for the European Open Science Cloud. *Inf. Serv. Use***2017**, *37*, 49–56. [CrossRef]
117. Brownsword,R.;Goodwin,M.*LawandtheTechnologiesoftheTwenty-FirstCentury*;CambridgeUniversityPress:Cambridge,UK, 2012.
118. Voigt,P.;VondemBussche,A.*TheEUGeneralDataProtectionRegulation(GDPR)*;SpringerInternationalPublishing: Berlin/Heidelberg, Germany, 2017.
119. Torrance,A.W.; Tomlinson,B. Patentsand theRegress ofUseful Arts.*ColumbiaSci.Technol.LawRev.***2019**,*10*, 130–168.
120. Mitchell,M.; Wu,S.; Zaldivar,A.; Barnes,P.; Vasserman,L.; Hutchinson,B.; Gebru,T.Modelcardsformodelreporting.In ProceedingsoftheConferenceonFairness2019,Accountability,andTransparency,Atlanta,GA,USA,29–31January2019; pp.220–229.
121. Baker,M.1500scientistslifttheli donreproducibility.*Nat.News* **2016**,*533*,452.[CrossRef][PubMed]
122. Tannenbaum, J.; Bennett, B.T. Russell and Burch's 3Rs then and now:The need for clarity in definition and purpose.*J. Am. Assoc. Lab. Anim. Sci.* **2015**, *54*, 120–132. [PubMed]
123. Eichler,H.G.;Pignatti,F.;Flamion,B.;Leufkens,H.;Breckenridge,A.Balancingearlymarketaccesstonewdrugswiththeneedforbenefit/risk data:Amountingdilemma.*Nat.Rev.Drug Discov.***2008**,*7*,818–826.[CrossRef][PubMed]
124. Hughes,J.P.;Rees,S.;Kalindjian,S.B.;Philpott,K.L.Principlesofearlydrugdiscovery.*Br.J.Pharmacol.***2011**,*162*,1239–1249. [CrossRef][PubMed]
125. Hulsen,T.Literatureanalysisofartificialintelligenceinbiomedicine.*Ann.Transl.Med.***2022**,*10*,1284.[CrossRef][PubMed]
126. Wilkinson, M.D.; Dumontier, M.; Aalbersberg, I.J.; Appleton, G.; Axton, M.; Baak, A.; Bouwman, J. The FAIR Guiding Principles forscientificdatamanagementandstewardship. *Sci. Data***2016**,*3*,160018. [CrossRef]

127. Brankovic´, M. Green chemical analysis: Main principles and current efforts towards greener analytical methodologies. *Anal. Methods* **2023**, *15*, 6631–6642. [CrossRef]
128. Rahwan, I.; Cebrian, M.; Obradovich, N.; Bongard, J.; Bonnefon, J.F.; Breazeal, C.; Jennings, N.R. Machine behaviour. *Nature* **2019**, *568*, 477–486. [CrossRef]
129. Karplus, M.; Petsko, G.A. Molecular dynamics simulations in biology. *Nature* **1990**, *347*, 631–639. [CrossRef]
130. Paul, S.M.; Mytelka, D.S.; Dunwiddie, C.T.; Persinger, C.C.; Munos, B.H.; Lindborg, S.R.; Schacht, A.L. How to improve R&D productivity: The pharmaceutical industry's grand challenge. *Nat. Rev. Drug Discov.* **2010**, *9*, 203–214. [PubMed]
131. Deliorman, M.; Ali, D.S.; Qasaimeh, M.A. Next-Generation Microfluidics for Biomedical Research and Healthcare Applications. *Biomed. Eng. Comput. Biol.* **2023**, *14*, 11795972231214387. [CrossRef] [PubMed]
132. Case, D.A.; Cheatham, T.E.; Darden, T.; Gohlke, H.; Luo, R.; Merz, K.M.; Woods, R.J. The Amber biomolecular simulation programs. *J. Comput. Chem.* **2005**, *26*, 1668–1688. [CrossRef] [PubMed]
133. Breinig, M.; Klein, F.A.; Huber, W.; Boutros, M. A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells. *Mol. Syst. Biol.* **2015**, *11*, 846. [CrossRef] [PubMed]
134. Tindall, M.J.; Cucurull-Sanchez, L.; Mistry, H.; Yates, J.W.T. Quantitative Systems Pharmacology and Machine Learning: A Match Made in Heaven or Hell? *J. Pharmacol. Exp. Ther.* **2023**, *387*, 92–99. [CrossRef] [PubMed]
135. Boran, A.D.; Iyengar, R. Systems approaches to polypharmacology and drug discovery. *Curr. Opin. Drug Discov. Dev.* **2010**, *13*, 297–309.
136. Kirchmair, J.; Göller, A.H.; Lang, D.; Kunze, J.; Testa, B.; Wilson, I.D.; Schneider, G. Predicting drug metabolism: Experiment and/or computation? *Nat. Rev. Drug Discov.* **2015**, *14*, 387–404. [CrossRef]
137. Oprea, T.I.; Gottfries, J. Chemography: The art of navigating in chemical space. *J. Comb. Chem.* **2001**, *3*, 157–166. [CrossRef]
138. Xia, S.; Chen, E.; Zhang, Y. Integrated Molecular Modeling and Machine Learning for Drug Design. *J. Chem. Theory Comput.* **2023**, *19*, 7478–7495. [CrossRef]
139. Pirard, B. The quest for novel chemical matter and the contribution of computer-aided de novo design. *Expert Opin. Drug Discov.* **2011**, *6*, 225–231. [CrossRef]
140. Ekins, S.; Puhl, A.C.; Zorn, K.M.; Lane, T.R.; Russo, D.P.; Klein, J.J.; Zahoránszky-Kőhalmi, G. Exploiting machine learning for end-to-end drug discovery and development. *Nat. Mater.* **2019**, *18*, 435–441. [CrossRef] [PubMed]
141. Lusher, S.J.; McGuire, R.; van Schaik, R.C.; Nicholson, C.D.; de Vlieg, J. Data-driven medicinal chemistry in the era of big data. *Drug Discov. Today* **2011**, *19*, 859–868. [CrossRef] [PubMed]
142. Good, A.C.; Krystek, S.R.; Mason, J.S. High-throughput and virtual screening: Core lead discovery technologies move towards integration. *Drug Discov. Today* **2000**, *5*, 61–69. [CrossRef] [PubMed]
143. Andrade, E.L.; Bento, A.F.; Cavalli, J.; Oliveira, S.K.; Freitas, C.S.; Marcon, R.; Schwanke, R.C.; Siqueira, J.M.; Calixto, J.B. Non-clinical studies required for new drug development—Part I: Early in silico and in vitro studies, new target discovery and validation, proof of principle and robustness of animal studies. *Braz. J. Med. Biol. Res.* **2016**, *49*, e5644. [CrossRef] [PubMed]
144. James, T.; Hristozov, D. Deep Learning and Computational Chemistry. *Methods Mol. Biol.* **2022**, *2390*, 125–151. [CrossRef] [PubMed]
145. Wells, J.A.; McClendon, C.L. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces. *Nature* **2007**, *450*, 1001–1009. [CrossRef]
146. Lyon, J. AI ethics in predictive modeling and precision medicine. *J. Mol. Biol.* **2019**, *431*, 4118–4134.
147. Karczewski, K.J.; Snyder, M.P. Integrative omics for health and disease. *Nat. Rev. Genet.* **2018**, *19*, 299–310. [CrossRef]
148. Gierend, K.; Waltemath, D.; Ganslandt, T.; Siegel, F. Traceable Research Data Sharing in a German Medical Data Integration Center With FAIR (Findability, Accessibility, Interoperability, and Reusability)-Geared Provenance Implementation: Proof-of-Concept Study. *JMIR Form Res.* **2023**, *7*, e50027. [CrossRef]
149. Shultz, M.D. Considerations for designing and prioritizing computational drug discovery. *SLAS Discov.* **2019**, *24*, 468–486.
150. Shabani, A.; Rajabi, S.; Alipanahi, N.; Ahmadi Teymourlouy, A. Key Factors to Improve Pharmaceutical Industry's R&D Productivity: A Case Study of Iranian Pharmaceutical Holding. *Med. J. Islam Repub. Iran.* **2022**, *36*, 117. [CrossRef] [PubMed]
151. Sullivan, J.A.; Dumont, J.R.; Memar, S.; Skirzewski, M.; Wan, J.; Mofrad, M.H.; Ansari, H.Z.; Li, Y.; Muller, L.; Prado, V.F.; et al. New frontiers in translational research: Touchscreens, open science, and the mouse translational research accelerator platform. *Genes Brain Behav.* **2021**, *20*, e12705. [CrossRef] [PubMed]
152. Goldman, M. The innovative medicines initiative: A European response to the innovation challenge. *Clin. Pharmacol. Ther.* **2012**, *91*, 418–425. [CrossRef] [PubMed]
153. Wang, Y.; Suzek, T.; Zhang, J.; Wang, J.; He, S.; Cheng, T.; Gindulyte, A. PubChem BioAssay: 2014 update. *Nucleic Acids Res.* **2014**, *42*, D1075–D1082. [CrossRef] [PubMed]
154. Chen, Y.; Elenee Argentinis, J.D. IBM Watson: How cognitive computing can be applied to big data challenges in life sciences research. *Clin. Ther.* **2016**, *38*, 688–701. [CrossRef] [PubMed]
155. Monge, A.; Arrault, A.; Marot, C. University–industry collaboration in drug discovery and developments: A matter of synergies. *Drug Discov. Today* **2011**, *16*, 1106–1114.
156. Pisani, E.; AbouZahr, C. Sharing health data: Good intentions are not enough. *Bull. World Health Organ.* **2010**, *88*, 462–466. [CrossRef]
157. Hamburg, M.A.; Collins, F.S. The path to personalized medicine. *N. Engl. J. Med.* **2010**, *363*, 301–304. [CrossRef]

158. McCarthy, M.I.; Abecasis, G.R.; Cardon, L.R.; Goldstein, D.B.; Little, J.; Ioannidis, J.P.; Hirschhorn, J.N. Genome-wide association studiesforcomplextraits: Consensus,uncertaintyandchallenges. *Nat.Rev.Genet.***2008**,*9*,356–369. [CrossRef]
159. Nelson,M.R.;Johnson,T.;Warren,L.;Hughes,A.R.;Chissoe,S.L.;Xu,C.F.;Waterworth,D.M.Thegeneticsofdrugefficacy: Opportunitiesandchallenges. *Nat. Rev. Genet.* **2016**,*17*,197–210. [CrossRef]
160. Mirnezami,R.;Nicholson,J.;Darzi,A.Preparingforprecisionmedicine.*N. Engl.J.Med.***2012**,*366*,489–491.[CrossRef][PubMed]
161. Garraway,L.A.;Lander,E.S.Lessonsfromthecancergenome.*Cell***2013**,*153*,17–37.[CrossRef][PubMed]
162. Piwek,L.;Ellis,D.A.;Andrews,S.;Joinson,A.Theriseofconsumerhealthwearables:Promisesandbarriers.*PLoS Med.***2016**,*13*,e1001953. [CrossRef] [PubMed]
163. Phillips,K.A.;AnnSakowski,J.;Trosman,J.;Douglas,M.P.;Liang,S.Y.;Neumann,P.Theeconomicvalueofpersonalized medicinetests: Whatweknowandwhatweneedtoknow. *Genet. Med.* **2014**,*16*,251–257. [CrossRef][PubMed]
164. Schneider,P.;Walters,W.P.;Plowright,A.T.Rethinkingdrugdesignintheartificialintelligenceera.*Nat.Rev.DrugDiscov.***2016**, *19*,353–364.[CrossRef][PubMed]
165. Gómez-Bombarelli,R.;Wei,J.N.;Duvenaud,D.;Hernández-Lobato,J.M.;Sánchez-Lengeling,B.;Sheberla,D.;Aspuru-Guzik, A.Automaticchemicaldesignusingadata-drivencontinuousrepresentationofmolecules.*ACSCent.Sci.***2018**,*4*,268–276.[CrossRef] [PubMed]
166. Wang, Y.; Yella, J.; Jegga, A.G. Transcriptomic Data Mining and Repurposing for Computational Drug Discovery. *MethodsMol. Biol.***2019**, *1903*, 73–95. [CrossRef]
167. Vapnik,V.*TheNatureofStatisticalLearningTheory*;Springer:Berlin/Heidelberg,Germany,2013.
168. Preuer, K.; Renz, P.; Unterthiner, T.; Hochreiter, S.; Klambauer, G. Fréchet ChemNet Distance:A Metric for Generative Models forMolecules in Drug Discovery.*J. Chem. Inf. Model.* **2018**, *58*, 1736–1741.[CrossRef]
169. Feng, Y.; Zhang, L.; Yi, Z. Breast cancer cell nuclei classification in histopathology images using deep neural networks.*Int.J. Comput.Assist.Radiol.Surg.***2018**,*13*,179–191. [CrossRef]